Low dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19: a proposal for a multi-centric prospective trial

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorAlgara, M.-
Autor(es): dc.creatorArenas, M.-
Autor(es): dc.creatorMarin, J.-
Autor(es): dc.creatorVallverdu, I.-
Autor(es): dc.creatorFernandez-Letón, P.-
Autor(es): dc.creatorVillar, J.-
Autor(es): dc.creatorFabrer, G.-
Autor(es): dc.creatorRubio, C.-
Autor(es): dc.creatorMontero, A.-
Data de aceite: dc.date.accessioned2026-02-09T12:53:02Z-
Data de disponibilização: dc.date.available2026-02-09T12:53:02Z-
Data de envio: dc.date.issued2020-07-06-
Data de envio: dc.date.issued2020-07-06-
Data de envio: dc.date.issued2020-09-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/41719-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S2405630820300549-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1170164-
Descrição: dc.descriptionBackground COVID-19 is a highly contagious viral infection with high morbidity that is draining health resources. The biggest complication is pneumonia, which has a serious inflammatory component, with no standardized treatment. Low-dose radiation therapy (LD-RT) is non-invasive and has anti-inflammatory effects that can interfere with the inflammatory cascade, thus reducing the severity of associated cytokine release and might be useful in the treatment of respiratory complications caused by COVID-19. Study design and methods This multicentric prospective clinical trial seeks to evaluate the efficacy of bilateral lung LD-RT therapy as a treatment for interstitial pneumonia in patients with COVID-19 for improving respiratory function. This prospective study will have 2 phases: I) an exploratory phase enrolling 10 patients, which will assess the feasibility and efficacy of low-dose lung irradiation, evaluated according to an increase in the PaO2/FiO2 ratio of at least 20% at 48–72 h with respect to the pre-irradiation value. If a minimum efficiency of 30% of the patients is not achieved, the study will not be continued. II) Non-randomized comparative phase in two groups: a control group, which will only receive pharmacological treatment, and an experimental arm with pharmacological treatment and LD-RT. It will include 96 patients, the allocation will be 1: 2, that is, 32 in the control arm and 64 in the experimental arm. The primary end-point will be the efficacy of LD-RT in patients with COVID-19 pneumonia according to an improvement in PaO2/FiO2. Secondary objectives will include the safety of bilateral lung LD-RT, an improvement in the radiology image, overall mortality rates at 15 and 30 days after irradiation and characterizing anti-inflammatory mechanisms of LD-RT by measuring the level of expression of adhesion molecules, anti-inflammatory cytokines and oxidative stress mediators.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceClinical and Translational Radiation Oncology-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subjectRadiotherapy-
Palavras-chave: dc.subjectPneumonia-
Título: dc.titleLow dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19: a proposal for a multi-centric prospective trial-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.